<DOC>
	<DOCNO>NCT01464359</DOCNO>
	<brief_summary>This trial propose build experience design maximize early ( day 3-14 ) late ( day 60-71 ) donor-derived natural killer ( NK ) cell expansion function vivo . The propose platform allow u unique opportunity compare vivo function transplant umbilical cord blood ( UCB ) source ( presume contain NK progenitor require `` education '' recipient ) .</brief_summary>
	<brief_title>T-Cell Depleted Double UCB Refractory AML</brief_title>
	<detailed_description>This single center study determine feasibility safety use myeloablative conditioning regimen follow ( day 0 ) transplantation double T-cell deplete ( TCD ) umbilical cord blood ( UCB ) unit unit few mononuclear cell ( MNCs ) /kg select overnight IL-2 activation prior infusion . Beginning day +3 , post transplant IL-2 administer thrice weekly , consecutive day , total 6 dos expand UCB derive progenitor cell . Post transplant immune suppression prophylaxis administer intent lessen toxicity allow allogeneic NK cell function longer provide well anti-leukemic therapy . However either UCB unit 5 % T-cells , patient receive either course IL-2 . Beginning day +60 transplantation , second course IL-2 administer thrice weekly , consecutive day , total 6 dos purpose enhance vivo expansion education NK cell derive engraft UCB cell .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Allopurinol</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<mesh_term>Etiracetam</mesh_term>
	<criteria>Aged 2 45 year acute myeloid leukemia ( AML ) meet one follow criterion : Primary induction failure define complete remission ( CR ) two three induction cycle ( blast limit ) . Relapsed AML low disease burden : For patient &gt; 21 45 year age : must &lt; 30 % marrow blast within 14 day enrollment least 28 day start last therapy . For patient 2 ≤ 21 year age : must &gt; 5 % marrow blast 3 induction attempt . Patients prior central nervous system ( CNS ) involvement eligible provide treated remission . CNS therapy ( chemotherapy radiation ) continue medically indicate protocol . Have acceptable organ function within 14 day study registration define : Renal : creatinine ≤ 2.0 mg/dL ( adult patient ) calculate creatinine clearance &gt; 40 ml/min ( pediatric patient ) Hepatic : bilirubin , aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) , alkaline phosphatase ( ALP ) ≤ 5 time upper limit normal Pulmonary function : diffusing lung capacity carbon monoxide correct hemoglobin ( DLCOcorr ) &gt; 50 % normal , ( oxygen saturation [ &gt; 92 % ] use child pulmonary function test ( PFT 's ) obtain ) Cardiac : leave ventricular ejection fraction ≥ 45 % Karnofsky Performance Status ≥ 70 % ( ≥ 16 year ) Lansky Play Score ≥ 50 ( pediatrics &lt; 16 year ) Women childbearing potential must agree use adequate contraception ( diaphragm , birth control pill , injection , intrauterine device [ IUD ] , surgical sterilization , subcutaneous implant , abstinence , etc . ) duration treatment . All patient question prior exposure antibody therapy ( include OKT3 , rituximab , trastuzumab , gemtuzumab ) without affect eligibility . Patients prior exposure blood sample collect human antimouse antibody ( HAMA ) . For patient prior antibody therapy exposure , action take . Voluntary write consent Active infection time enrollment document fungal infection within 3 month unless clearance Infectious Disease Evidence HIV infection know HIV positive serology Pregnant breast feeding . If &lt; = 21 year old , prior myeloablative transplant within last 6 month . If &gt; 21 year old prior myeloablative allotransplant autologous transplant prior condition regimen include total body irradiation ( TBI ) , busulfan/cyclophosphamide ( BU/CY ) prep use If &gt; 21 year old extensive prior therapy include &gt; 12 month alkylator chemotherapy ( etoposide &gt; 100 mg/m^2 x 5 day , cyclophosphamide &gt; 1 gm/m^2 mitoxantrone &gt; 8 gm/m^2 ) deliver 34 week interval &gt; 6 month alkylator therapy ( ) extensive radiation ( determine Radiation Oncology , e.g . mantle irradiation Hodgkin 's ) and/or prior radiation therapy make patient ineligible TBI . Known hypersensitivity study agent</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>umbilical cord blood transplant</keyword>
</DOC>